The first clue in Olivier Roux’s career is not the word “sales.” It is the word “quality.” In May 2002, newly out of Indiana University Bloomington, Roux began as a quality-control specialist at Pfizer. The work lived close to instruments, specifications and evidence. A result either held up or it did not. A method either behaved predictably or it sent everyone back to the bench. There was little room for decorative certainty.
That beginning matters because Roux now sits on the other side of the pharmaceutical manufacturing conversation. As Senior Director of CMO Sales at Curia, he helps customers decide where complicated active ingredients should be made, how a process might scale and what sort of partner can carry it through. He arrived at that commercial role by the scenic route: reference standards, method validation, method transfer, analytical science, technical development, regulatory affairs, business development, strategic marketing and account management. Every stop added a new answer to the same question. What does it take to make a scientific promise dependable?
The apprenticeship nobody calls an apprenticeship
Roux’s first thirteen years were a patient education in consequence. After quality control came responsibility for reference standards, the materials against which other measurements are judged. Then came method validation and transfer, where a procedure has to survive the journey from one setting to another without losing its meaning. By 2007 he was a senior scientist. In 2012, his remit expanded into technical development and regulatory affairs.
The progression reads almost too neatly in hindsight. First learn to measure. Then learn to reproduce the measurement. Then learn what happens when the process changes hands. Then learn how technical decisions meet regulatory expectations. The titles changed, but each assignment dealt with the frailty of handoffs. Pharmaceutical manufacturing has many of them: scientist to engineer, laboratory to plant, sponsor to contractor, development batch to commercial run. Knowledge can disappear in the gap unless someone knows what must travel with it.
“For the client, the key benefit was that there was continuity from early clinical phase all the way to commercial.”Olivier Roux, on carrying a process through scale-up
Continuity is not a thrilling word. It rarely gets printed on a conference tote bag. It is, however, the idea Roux returns to when he explains manufacturing. In one publicly described project, a biotech arrived with a corticosteroid candidate whose synthetic route and crystallization needed work. The team optimized both at laboratory scale, advanced the process on the same equipment platform and eventually moved it into multi-ton commercial production. The clever part was not merely reaching the larger vessel. It was keeping the learning intact along the way.
The knowledge must survive the handoff
Crossing the room
In March 2015, Roux moved into business development for Pfizer CentreOne’s API contract-manufacturing services. It was a functional crossing, but not a clean break. The new job required him to translate the facts of production into the language of customers. A reactor is capacity to an engineer, capital to an operator, risk to a regulator and a delivery promise to a client. Roux had already met the first three interpretations before being asked to sell the fourth.
Two years later, he became a senior manager in global strategic marketing. In 2020, he moved into senior account management. Pfizer CentreOne material later listed him as Americas Sales Lead for APIs and intermediates. By then, the former quality specialist had spent years explaining a factory’s capabilities to people whose own programs carried deadlines, filings and supply obligations. Technical detail was no longer only something to document. It was something to make legible.
The useful salesperson in this corner of industry is not the one who can make complexity vanish. Complexity has a habit of returning, usually on a Friday afternoon. The useful salesperson knows which complexity belongs in the conversation. Particle size may sound like a narrow specification until it affects downstream performance. Aseptic processing may sound like a facility checkbox until the molecule cannot tolerate other treatment. Segregation may look like floor-plan trivia until cross-contamination becomes the central risk.
Roux speaks comfortably in those particulars. In a 2026 discussion, he described chemistry, fermentation, bioengineering and enzymatic reactions as parts of an evolving production toolkit. He talked through controlled crystallization, milling and micronization. He explained why specialized molecules can demand isolated plants and contained equipment. There was no attempt to turn manufacturing into magic. His subject was the organized removal of unpleasant surprises.
“Steroids are mature markets that have been around for 80 years, but it’s not a static market to this day.”Olivier Roux, 2026
The sentence contains Roux’s operating tension. Mature does not mean settled. Familiar molecules can acquire new formulations, tighter expectations and altered economics. Old chemistry meets new process technology. A market with history still manages to invent fresh headaches. The experienced operator earns his keep by recognizing which parts of the history remain useful and which parts need revisiting.
A career drawn as a process flow
Roux joined Curia in April 2025. The move changed the company name and broadened the network he could discuss, but the career logic remained intact. Curia works across discovery, development and manufacturing. Roux arrived with the lived sequence of someone who had watched a technical result turn into a regulatory requirement, a service offering and, finally, a customer commitment.
His public activity since the move has followed that logic. He has highlighted manufacturing sites and complex API capabilities, circulated discussions of multi-site CDMO strategy and appeared on the Beyond Biotech podcast to explain how partners handle scale, supply problems and emerging process technology. In July 2026, he gave a detailed account of Curia’s approach to steroid and hormone manufacturing, including a second case in which a team confronted a disrupted supply process, variable yields and impurity challenges under tight timelines.
The geography of the job has widened even as Roux has remained based in southwest Michigan. His work now connects customer conversations with a network that includes specialized European manufacturing. That distance makes translation more important, not less. A capability described in a brochure has to correspond to equipment, teams and operating history at a real site. A customer request formed in one market has to arrive intact in another. Roux’s bilingual French and English background is a documented detail, but the deeper bilingualism in his career is functional: he can speak with the caution of the laboratory and the momentum of the commercial organization. The two dialects do not always agree. His value sits in the negotiation between them.
The anecdote is revealing because the solution was not a heroic flash. The team troubleshot the chemistry, improved the yield, transferred the process to the plant, stabilized it and coordinated the necessary documentation. It is an uncinematic sequence of verbs. It is also how industrial competence usually looks: diagnose, adjust, transfer, document, repeat.
The quiet advantage of having been there
There is a fashionable idea that specialists must become generalists to lead. Roux’s path suggests a more precise version. The specialist can keep the specificity and learn where to carry it. His advantage in a customer conversation is not that he has escaped the bench. It is that he remembers what the bench demands. He knows that the confident sentence in a proposal eventually has to survive contact with equipment, data and people on a shift.
That memory creates a useful kind of restraint. Roux’s public explanations favor process over personality. He names the control, the facility, the scale and the handoff. When he argues that clients should seek a partner rather than a supplier, the distinction is practical. A supplier delivers an item. A partner has to remain useful when the yield varies, the impurity appears or the next scale exposes a hidden assumption.
“They need to have a proven regulatory track record.”Olivier Roux, on choosing a manufacturing partner
The line is almost aggressively sensible. Proven means the promise has a past. Track record means the evidence extends beyond a single good day. After twenty-four years moving from measurements to markets, Roux has built a career around that preference for proof.
A molecule refuses flattery. It may accept a better route, a more careful crystallization, a controlled particle size or a smarter piece of equipment. It may reward patience. It remains gloriously indifferent to the seniority of everyone in the meeting. Roux learned that lesson early, when his title was quality-control specialist. His later titles did not replace it. They simply gave him more rooms in which to put it to work.